Evidence map›Paper›PMID 40663784›Full record

ArticleBlood2025

The acute myeloid leukemia microenvironment impairs neutrophil maturation and function through NF-κB signaling.

Paran Goel, Sajesan Aryal, Alana M Franceski, Valeriya Kuznetsova, Amanda Costa, Francesca Luca, Ashley N Connelly, Daniel W Phillips, Caroline C Ennis, Brittany M Curtiss and 15 more

Abstract read
In one paragraph

Article in Blood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Immune interplay between sepsis and haematological malignancies.Intensive care medicine experimental · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Paran GoelDivision of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL.ORCID 0009-0000-6494-632X
Sajesan AryalDivision of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0001-6154-0586
Alana M FranceskiDivision of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0002-1895-5337
Valeriya KuznetsovaDivision of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0002-1329-4736
Amanda CostaDivision of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0002-1898-2896
Francesca LucaDivision of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0001-8431-475X
Ashley N ConnellyDivision of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL.
Daniel W PhillipsDivision of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL.
Caroline C EnnisDivision of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL.
Brittany M CurtissDivision of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL.
Sourajeet KarfaDivision of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL.ORCID 0009-0008-8767-0328
Brittany L CrownDivision of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL.ORCID 0009-0001-0206-1507
Christina R LarsonDivision of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL.ORCID 0009-0003-3215-5648
Estelle CarminitaDepartment of Surgery, Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-8544-4879
Virginia CamachoDepartment of Surgery, Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Doug WelschDivision of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0002-3873-9586
Changde ChengDivision of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0002-2458-2522
Asumi YokotaLaboratory of Stem Cell Regulation, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Isidoro CoboDivision of Clinical Immunology and Rheumatology, Department of Medicine, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0002-2065-535X
Hideyo HiraiLaboratory of Stem Cell Regulation, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Rui LuDivision of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0003-1593-2612
Ravi BhatiaDivision of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL.
Pran K DattaDivision of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL.
P Brent FerrellDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Robert S WelnerDivision of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0003-2498-9469

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Omer Jamy · 1985 to 2026
$165.9M
Transcriptional and epigenetic heterogeneity of stem/progenitor cellsP01HL131477 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI Jason Daniel Buenrostro · 2017 to 2026
$24.6M
IMMUNOLOGIC DISEASES AND BASIC IMMUNOLOGYT32AI007051 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Laurie Ellen Harrington · 1985 to 2026
$13.1M
Training Program in Rheumatic and Musculoskeletal Diseases ResearchT32AR069516 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI John D Mountz · 2016 to 2026
$2.6M
Role of bone marrow Tregs in maintaining stromal cell functionR01HL150078 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WELNER, ROBERT S · 2020 to 2023
$1.5M
Multi-parameter, analytic flow cytometerS10OD032296 · OD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RANDALL, TROY D · 2022 to 2022
$464k
NCI NIH HHS P30 CA013148NHLBI NIH HHS P01 HL131477NHLBI NIH HHS R01 HL150078NIAID NIH HHS T32 AI007051NIAMS NIH HHS T32 AR069516NIH HHS S10 OD032296
6 · The paper itself

Abstract

abstractAcute myeloid leukemia (AML), an aggressive hematological malignancy, is driven by oncogenic mutations in stem and progenitor cells that give rise to AML blasts. Although these mutations are well characterized, their impact on healthy hematopoiesis, those blood cells exposed to AML but not mutated, has not been well characterized. Because the marrow is the major site for granulopoiesis, neutrophils are heavily influenced by AML pathobiology. Indeed, most patients with AML report neutropenia, rendering them susceptible to infections. However, because AML studies use peripheral blood mononuclear cells devoid of neutrophils, the characterization of neutrophil dysfunction remains poorly understood. To investigate AML-exposed neutrophils, a preclinical AML mouse model in which primary leukemic cells were transplanted into nonirradiated neutrophil reporter (Ly6G-tdTomato; Catchup) hosts was used. Neutrophils could not completely mature, suggesting impaired granulopoiesis. Single-cell transcriptomics of AML-exposed neutrophils revealed higher inflammation signatures and expression of CD14, an inflammatory marker. To address the factors contributing to this biology, an ex vivo cytokine screen was performed on marrow neutrophils, and it identified that nuclear factor κB signaling drove CD14 expression. AML-exposed neutrophils displayed widespread chromatin remodeling, and de novo motif discovery predicted increased binding sites for CCAAT enhancer-binding proteins and interferon regulatory factors. Moreover, AML-exposed neutrophils inhibited T-cell proliferation, highlighting their immune-suppressive capability. Finally, a similar biology of immature, inflammatory neutrophils was found in patients with AML, again indicating dysregulated granulopoiesis. Collectively, these data show that AML-associated inflammation alters neutrophil granulopoiesis, impairs neutrophil function, and drives immunosuppression, thereby contributing to patient susceptibility to infection.

Indexed as

Leukemia, Myeloid, AcuteNeutrophilsNF-kappa BSignal TransductionTumor MicroenvironmentAnimalsCell DifferentiationHumansMiceNF-kappa B

Identifiers

PMID40663784
PMCPMC12755217

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.